Trial reportJournal of lipid research2014
Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia.
Trial report in Journal of lipid research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 41 citations in OpenAlex.
- Effectiveness of LDL Apheresis Techniques for Reducing LDL-C in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- The functions of apolipoproteins and lipoproteins in health and disease.Molecular biomedicine · 2024Review
- Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a).Scientific reports · 2024Article
- Extracellular Vesicles in Diagnosing Chronic Coronary Syndromes the Bumpy Road to Clinical Implementation.International journal of molecular sciences · 2020Review
- Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles.Journal of clinical medicine · 2019Review
- Article
- Extracellular vesicles: biomarkers and regulators of vascular function during extracorporeal circulation.Oncotarget · 2018Review
- Molecular interactions at the surface of extracellular vesicles.Seminars in immunopathology · 2018Review
- Routine Screening Method for Microparticles in Platelet Transfusions.Journal of visualized experiments : JoVE · 2018Article
- Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles.International journal of molecular sciences · 2017Article
- The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.Cardiovascular drugs and therapy · 2017Review
- Extracellular vesicles as mediators of vascular inflammation in kidney disease.World journal of nephrology · 2016Review
- Characterisation of adipocyte-derived extracellular vesicles released pre- and post-adipogenesis.Journal of extracellular vesicles · 2015Article
- The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs) are submicron vesicles released from the plasma membrane of cells. MPs, particularly platelet-derived MPs, are increasingly being linked to the pathogenesis of many diseases. We aimed to characterize the effect of apheresis on MP size, concentration, cellular origin, and fatty acid concentration in individuals with familial hypercholesterolemia (FH). Plasma and MP samples were collected from 12 individuals with FH undergoing routine apheresis. Tunable resistive pulse sensing (np200) and nanoparticle tracking analysis measured a fall in MP concentration (33 and 15%, respectively; P < 0.05) pre- to post-apheresis. Flow cytometry showed MPs were predominantly annexin V positive and of platelet (CD41) origin both pre- (88.9%) and post-apheresis (88.4%). Fatty acid composition of MPs differed from that of plasma, though apheresis affected a similar profile of fatty acids in both compartments, as measured by GC-flame ionization detection. MP concentration was also shown to positively correlate with thrombin generation potential. In conclusion, we show apheresis nonselectively removes annexin V-positive platelet-derived MPs in individuals with FH. These MPs are potent inducers of coagulation and are elevated in CVD; this reduction in pathological MPs could relate to the long-term benefits of apheresis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.